Stryker completes acquisition of Inari Medical
Written by Emily J. Thompson, Senior Investment Analyst
Acquisition Announcement: Stryker has completed the acquisition of Inari Medical, which specializes in innovative solutions for venous thromboembolism (VTE) clot removal without thrombolytic drugs.
Complementary Product Portfolio: The acquisition enhances Stryker's position in the VTE segment and complements its Neurovascular business with Inari's mechanical thrombectomy solutions, including the FlowTriever and ClotTriever systems.
Analyst Views on SYK
Wall Street analysts forecast SYK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SYK is 432.38 USD with a low forecast of 400.00 USD and a high forecast of 456.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
15 Buy
3 Hold
0 Sell
Strong Buy
Current: 362.490
Low
400.00
Averages
432.38
High
456.00
Current: 362.490
Low
400.00
Averages
432.38
High
456.00
About SYK
Stryker Corporation is a medical technology company. The Company offers products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Its segments include MedSurg and Neurotechnology and Orthopaedics. Its MedSurg products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical). Neurotechnology includes neurosurgical, neurovascular and craniomaxillofacial implant products. Its Orthopaedics products primarily include implants used in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. The Company also offers solutions for venous thromboembolism clot removal without the use of thrombolytic drugs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
